Latuda Dose Increase from 80 mg
For adults with schizophrenia on Latuda 80 mg, the next dose increase is to 120 mg daily, with a maximum of 160 mg daily if needed. 1
Dosing Algorithm Based on Indication
For Schizophrenia (Adults)
The FDA-approved dosing for adult schizophrenia establishes that Latuda is effective in the range of 40-160 mg daily, with 160 mg as the maximum dose 1. If you're treating schizophrenia and the patient is currently on 80 mg, increase to 120 mg daily, and if further improvement is needed, you can go up to 160 mg daily.
Critical timing consideration: If the patient has been on 80 mg for only 2 weeks and shows inadequate response (defined as <20% reduction in PANSS score), dose escalation to 160 mg produces significantly better outcomes than continuing at 80 mg (effect size 0.52) 2. This means early non-responders benefit substantially from prompt dose escalation rather than waiting longer at the subtherapeutic dose.
For Bipolar Depression (Adults)
Do not increase beyond 80 mg if treating bipolar depression. The FDA label clearly states the maximum dose for bipolar depression is 120 mg daily, but importantly, the higher dose range (80-120 mg) did not provide additional efficacy compared to the lower range (20-60 mg) 1. For bipolar depression, most patients respond adequately at 20-40 mg daily 3.
For Adolescents (13-17 years, Schizophrenia)
80 mg is already the maximum dose for adolescents with schizophrenia—do not increase further 1.
When to Increase the Dose
- Assess response at 2 weeks: If PANSS reduction is <20%, this identifies non-responders who will benefit from dose escalation 2
- Standard reassessment intervals: After initial titration, reassess at 14-21 day intervals before making dose changes 4
- Do not increase more frequently than every 2 weeks to allow adequate time to assess response
Important Caveats
Dose limitations apply in specific populations:
- Moderate/severe renal impairment: Maximum 80 mg daily (do not exceed current dose) 1
- Moderate hepatic impairment: Maximum 80 mg daily 1
- Severe hepatic impairment: Maximum 40 mg daily (must decrease current dose) 1
- Concurrent moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole): Maximum 80 mg daily 1
Common pitfall: The 120 mg dose demonstrates the fastest and most significant symptom reduction in real-world studies, with better treatment persistence than 160 mg 5. This suggests 120 mg may be the optimal target dose for most patients, with 160 mg reserved for those who show partial response at 120 mg.
Administration requirement: Always take with at least 350 calories of food—absorption increases 2-fold (AUC) and 3-fold (Cmax) with food 1. Avoid grapefruit juice, which inhibits CYP3A4 1.